Stereotactic radiotherapy for lung cancer: Influence of prescription modality on clinical outcome.

Date publication

août 2025

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine

Tous les auteurs :
Antoni D, Schick U, Jarnet D, Josset S, Mazurier J, Parent L, Pasquier D, Lacornerie T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40840170

Résumé

Stereotactic body radiotherapy, also referred to extreme hypofractionation, uses advanced delivery techniques to administer high radiation doses per fraction. Stereotactic body radiotherapy has led to a real revolution for the treatment in localized non-small cell lung cancer. Recognized as the standard treatment for inoperable early-stage non-small cell lung cancer, there is an increasing use of stereotactic body radiotherapy in complex situations related to patient or tumour characteristics. The aim of this review was to report the current evidence so far, and to assess specificities of this irradiation technique, especially in terms of dose prescription modalities.

Mots clés

Dose, Dose prescription modalities, Lung cancer, Prescription, Radiothérapie en conditions stéréotaxiques, Stereotactic body radiotherapy, Tumeur pulmonaire

Référence

Cancer Radiother. 2025 08 20;29(5-6):104710